Our Science
A Modular Theranostic Platform Designed for Precision
From imaging to therapy — built to adapt, scale and deliver.
GAIASO’s technology platform is engineered to unlock the full potential of theranostics for female cancers. Built on modular molecular scaffolds, it enables the rapid development of highly specific agents that pair diagnostic imaging with targeted therapy.
Rather than adapting existing solutions, GAIASO designs molecules around female cancer biology—supporting relevance, precision and translational efficiency from the outset.
How It Works
Our integrated approach brings diagnostic and therapeutic development together through:
- Target selection informed by deep understanding of female cancer biology
- Ligand engineering to optimise specificity, stability and tumour penetration
- Isotope pairing chosen for both imaging clarity and therapeutic effect
- Integrated development from diagnostics through to therapy
This integrated design supports a clear transition from seeing disease to treating it.
Why It’s Different
GAIASO’s platform is differentiated by:
- Design rooted in female biology
- Smaller, engineered binders enabling deep tumour penetration
- Modular architecture that allows rapid adaptation across indications
- Seamless translation from imaging to therapy, reducing development friction
Scalability and Future Applications
The platform is inherently adaptable. As the pipeline grows, it enables expansion across multiple female cancer indications and isotope pairings - supporting long‑term value creation and sustained innovation.
The GAIASO Platform
Built for best‑in‑class theranostics.
The GAIASO platform is designed so every critical element works together to maximise impact:
- Strong and persistent tumour binding
- Deep tumour penetration via circulation
- High tumour accumulation with long retention
- Rapid clearance from healthy organs
- Modular optimisation across targets and isotopes
- Fast translation from discovery to clinic
Affilin® Technology
Next‑generation targeted therapeutic proteins.
Affilins® are small, human‑origin scaffold proteins engineered for precision targeting.
Compared with antibodies, Affilins® are:
- Significantly smaller, enabling deep tumour penetration
- Highly stable and robust
- Non‑glycosylated, homogeneous and scalable
- Designed for high affinity, selective binding
- Expected to have low immunogenic potential
Want to get in touch?
Fill out our form and we'll get back to you shortly.
* Please note, all fields are mandatory
Prefer E-Mail? You can reach us directly at [email protected]
"*" indicates required fields